Spots Global Cancer Trial Database for first line treatment
Every month we try and update this database with for first line treatment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | NCT01950182 | Breast Cancer | Endocrine thera... Chemotherapy co... | 18 Years - 75 Years | Sun Yat-sen University | |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | NCT06390059 | Metastatic Panc... | Tumor Treating ... Atezolizumab Gemcitabine nab-paclitaxel | 18 Years - | NovoCure Ltd. | |
| Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer | NCT00222469 | Metastatic Panc... | bevacizumab gemcitabine oxaliplatin | 18 Years - | University of Oklahoma | |
| Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) | NCT05321212 | Carcinoma, Non-... Immunotherapy | 18 Years - | University Hospital, Brest | ||
| A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung | NCT01154140 | Non Squamous Lu... | treatment treatment | 18 Years - | Pfizer | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| First Line Ovarian Cancer Treatment - Cohort Study | NCT01832415 | Epithelial Ovar... | Bevacizumab | 18 Years - | ARCAGY/ GINECO GROUP | |
| Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | NCT00453635 | Breast Cancer | Docetaxel Carboplatin Herceptin Vinorelbine | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer | NCT00315185 | Carcinoma, Non-... | Cetuximab | 18 Years - | Fox Chase Cancer Center | |
| Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer | NCT02767661 | Breast Cancer | Capecitabine Aromatase Inhib... | 18 Years - 70 Years | Sun Yat-sen University | |
| Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma | NCT04316520 | Metastatic Rena... | Ketogenic diet | 18 Years - | University Hospital, Angers | |
| Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) | NCT05321212 | Carcinoma, Non-... Immunotherapy | 18 Years - | University Hospital, Brest | ||
| A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung | NCT01154140 | Non Squamous Lu... | treatment treatment | 18 Years - | Pfizer | |
| Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer | NCT02322593 | Gastric Cancer | TAS-118 plus Ox... S-1 plus Cispla... | 20 Years - | Taiho Pharmaceutical Co., Ltd. | |
| MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma | NCT01443065 | Malignant Neopl... Malignant Neopl... | Oxaliplatin Folinic Acid 5-fluoro-uracil panitumumab AMG102 | 18 Years - | UNICANCER | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT01274351 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis | |
| IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | NCT00200681 | Multiple Myelom... | Velcade | 18 Years - 65 Years | Nantes University Hospital | |
| Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer | NCT02322593 | Gastric Cancer | TAS-118 plus Ox... S-1 plus Cispla... | 20 Years - | Taiho Pharmaceutical Co., Ltd. | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery | NCT02535351 | Clear-cell Meta... | sunitinib or pa... Cytoreductive n... | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer | NCT00315185 | Carcinoma, Non-... | Cetuximab | 18 Years - | Fox Chase Cancer Center | |
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | NCT01306942 | Metastatic Brea... | Dasatinib Trastuzumab Paclitaxel | 18 Years - | Spanish Breast Cancer Research Group | |
| Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer | NCT00222469 | Metastatic Panc... | bevacizumab gemcitabine oxaliplatin | 18 Years - | University of Oklahoma | |
| IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | NCT00200681 | Multiple Myelom... | Velcade | 18 Years - 65 Years | Nantes University Hospital | |
| Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | NCT03586999 | Peripheral T Ce... | Nivolumab Etoposide Prednisolone Oncovin Cyclophosphamid... Hydroxydaunorub... | 18 Years - 80 Years | University of Colorado, Denver | |
| Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer | NCT05761977 | Small-cell Lung... Extensive-stage... | 18 Years - | Hellenic Cooperative Oncology Group | ||
| First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin | NCT00982111 | Non Small Cell ... | Pemetrexed Cisplatin Necitumumab | 18 Years - | Eli Lilly and Company | |
| POSITIVE - Study (Part III) Heidelberg | NCT02055508 | Advanced NSCLC First Line Trea... | Exercise Interv... Care-Management... | 18 Years - | German Cancer Research Center | |
| First Line Ovarian Cancer Treatment - Cohort Study | NCT01832415 | Epithelial Ovar... | Bevacizumab | 18 Years - | ARCAGY/ GINECO GROUP | |
| Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer | NCT01980212 | Advanced Non-sm... First Line Trea... Thioredoxin Red... Carcinoembryoni... Progression | 18 Years - 80 Years | Hunan Province Tumor Hospital | ||
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | NCT01306942 | Metastatic Brea... | Dasatinib Trastuzumab Paclitaxel | 18 Years - | Spanish Breast Cancer Research Group | |
| A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients | NCT01228734 | Metastatic Colo... | Cetuximab Oxaliplatin Folinic Acid 5Fluorouracil | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy | NCT01563588 | Non Metastatic ... | dietaty educati... | 18 Years - 70 Years | Centre Jean Perrin | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients | NCT00453635 | Breast Cancer | Docetaxel Carboplatin Herceptin Vinorelbine | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Exercise in Patients With Advanced Non-small Cell Lung Cancer | NCT06374160 | Advanced Lung C... First Line Trea... Second Line Tre... NSCLC Stage IV NSCLC Stage III... Palliative Trea... NSCLC Stage III... | Exercise interv... | 18 Years - | University Hospital, Essen | |
| A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer | NCT00477711 | Gastric Cancer | cetuximab, cisp... | 18 Years - 75 Years | Peking University | |
| The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma | NCT04356872 | Sarcoma, Soft T... | Sintilimab Doxorubicin Hyd... Ifosfamide | 18 Years - 75 Years | Fudan University | |
| Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | NCT00205751 | Multiple Myelom... | Thalidomide/Dex... | 19 Years - | Austrian Forum Against Cancer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
